

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

CHANGE OF AUDITORS

This announcement is made by the board of directors (the “**Board**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”, which together with its subsidiaries are collectively referred to as the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board announces that Crowe (HK) CPA Limited (“**Crowe**”) has resigned as the auditor of the Company with effect from 8 July 2020 after taking into account various factors, including the professional risk associated with the audit, the level of audit fees and the availability of its internal resources in light of its current work flows. Crowe has confirmed in writing that there are no matters in connection with its resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board and the audit committee of the Company (the “**Audit Committee**”) confirm that there is no disagreement between Crowe and the Company and there are no other matters in respect of the change of auditors that need to be brought to the attention of the Shareholders.

The Board confirms that Crowe has not yet commenced any review or audit work of the Group for the six months ended 30 June 2020 or for the financial year ending 31 December 2020. It is expected that the change of auditors will not have any material impact on the interim review and the release of interim results of the Group for the six months ended 30 June 2020.

The Board has identified and, with the recommendation of the Audit Committee, proposes to appoint Ernst & Young (“**EY**”) as the new auditor of the Group to fill the causal vacancy following the resignation of Crowe and to hold office until the conclusion of the next annual general meeting of the Company, subject to the completion of relevant audit engagement acceptance procedure and the formal acceptance of EY. Pursuant to Article 29.2 of the articles of association of the Company, the Board may fill any causal vacancy in the office of the Company’s auditor. Accordingly, no extraordinary general meeting will be held for such purpose. The Company is arranging for the engagement of EY and will make further announcement(s) in this regard as and when appropriate.

The Board would take this opportunity to express its gratitude to Crowe for their professional services rendered to the Group in the past.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 8 July 2020

As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive directors of the Company are Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang.